efruxifermin
Recombinant proteinexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Feb 16, 2021 (NCT04767529)
Timeline
Indications
Mechanism of action
- KlothoAGONIST
KL agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594389 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06528314 | Phase 3 | Sep 4, 2024 | Akero Therapeutics, Inc |
| NCT06215716 | Phase 3 | Dec 1, 2023 | Akero Therapeutics, Inc |
| NCT06161571 | Phase 3 | Nov 10, 2023 | Akero Therapeutics, Inc |
| NCT05039450 | Phase 2 | Jul 30, 2021 | Akero Therapeutics, Inc |
| NCT04767529 | Phase 2 | Feb 16, 2021 | Akero Therapeutics, Inc |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akero Therapeutics, Inc | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1